{"id":5869,"date":"2025-04-08T11:04:12","date_gmt":"2025-04-08T15:04:12","guid":{"rendered":"https:\/\/cqdm.org\/?p=5869"},"modified":"2025-04-08T11:05:46","modified_gmt":"2025-04-08T15:05:46","slug":"congratulations-to-synucure-therapeutics-on-securing-2-8m-in-funding","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/congratulations-to-synucure-therapeutics-on-securing-2-8m-in-funding\/","title":{"rendered":"Congratulations to Synucure Therapeutics on securing $2.8M in funding!"},"content":{"rendered":"\n<p>Congratulations to <a href=\"https:\/\/synucure.com\/\" target=\"_blank\" rel=\"noopener\">Synucure Therapeutics<\/a>, which has just completed a $2.8 million financing round, with 50% of the funding coming from the Government of Qu\u00e9bec through <a href=\"https:\/\/www.linkedin.com\/company\/investissement-quebec\/\" target=\"_blank\" rel=\"noopener\">Investissement Qu\u00e9bec<\/a> as part of the Impulsion PME program.\ud83d\udc4f<br><br><a href=\"https:\/\/www.linkedin.com\/company\/cqdm\/\" target=\"_blank\" rel=\"noopener\">CQDM<\/a> is proud to have supported this project by acting as an advisor and referring entity, helping facilitate access to this crucial funding to advance their innovation.<br><br>Synucure Therapeutics, specialized in the development of innovative treatments for Parkinson\u2019s disease, is reaching a key milestone to accelerate its research efforts and advance promising therapeutic solutions.<br>We wish them continued success in the next steps of their development!<br><br>\ud83d\udcc4 Read the full press release \ud83d\udc49<a href=\"https:\/\/lnkd.in\/eREJWbyv\" target=\"_blank\" rel=\"noopener\">https:\/\/lnkd.in\/eREJWbyv<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Congratulations to Synucure Therapeutics, which has just completed a $2.8 million financing round, with 50% of the funding coming from the Government of Qu\u00e9bec through Investissement Qu\u00e9bec as part of the Impulsion PME program.\ud83d\udc4fCQDM is proud to have supported this project by acting as an advisor and referring entity, helping facilitate access to this crucial&hellip;<\/p>\n","protected":false},"author":2,"featured_media":5867,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1,18],"tags":[],"class_list":["post-5869","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-news","category-news-from-the-industry"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/5869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=5869"}],"version-history":[{"count":1,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/5869\/revisions"}],"predecessor-version":[{"id":5870,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/5869\/revisions\/5870"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/5867"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=5869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=5869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=5869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}